

Chiral Cyclohexane 1,3-Diones as Inhibitors of Mutant SOD1-Dependent Protein Aggregation for the Treatment of ALS

Yinan Zhang,[†] Radhia Benmohamed,[‡] Wei Zhang,[†] Jinho Kim,[§] Christina K. Edgerly,[§] Yaoqiu Zhu,^{||} Richard I. Morimoto,[⊥] Robert J. Ferrante,[§] Donald R. Kirsch,[‡] and Richard B. Silverman^{*,†}

[†]Department of Chemistry, Department of Molecular Biosciences, Chemistry of Life Processes Institute, Center for Molecular Innovation and Drug Discovery, Northwestern University, Evanston, Illinois 60208-3113, United States

[‡]Cambria Pharmaceuticals, Cambridge, Massachusetts 02142, United States

[§]Neurological Surgery, Neurology, and Neurobiology Departments, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, United States, and the Geriatric Research Educational and Clinical Center (00-GR-H), V.A. Pittsburgh Healthcare System, 7180 Highland Drive, Pittsburgh, Pennsylvania 15206, United States


^{||}MetabQuest Research & Consulting, Beijing, 100871, China

[⊥]Department of Molecular Biosciences, Rice Institute for Biomedical Research, Northwestern University, Evanston, Illinois 60208-3500, United States

Supporting Information

ABSTRACT: Cyclohexane 1,3-diones were identified as a class of molecules exhibiting a protective effect against mutant SOD1 induced toxicity in PC-12 cells, but an optimized analogue had little or no effect on life extension in the G93A SOD1 mouse model for amyotrophic lateral sclerosis (ALS). Additional testing showed that these compounds were inactive in neurons, and further analogue synthesis was carried out to identify compounds with neuronal activity. Starting from two racemic derivatives that were active in cortical neurons, two potent analogues (**1b** and **2b**) were resolved, which were protective against mutant SOD1 induced toxicity in PC-12 cells. Both compounds were found to be active in cortical neurons and presented good ADME profiles in vitro. On the basis of these results, an ALS mouse trial with **1b** was carried out, which showed slightly greater life extension than the FDA-approved ALS drug riluzole, thereby validating cyclohexane 1,3-diones as a novel therapeutic class for the treatment of ALS.

KEYWORDS: Cyclohexane 1,3-diones, superoxide dismutase 1 (SOD1), protein aggregation, amyotrophic lateral sclerosis (ALS), mutant SOD1, PC-12 cells, cortical neurons



Amyotrophic lateral sclerosis (ALS) is a rare and fatal neurodegenerative disease characterized by progressive motor neuron loss in the central and peripheral neuron systems, leading to clinical muscle atrophy, paralysis, and final death from respiratory failure, generally, in 3–5 years.¹ It is estimated that the incidence of ALS is 1–2 cases per 100,000 people, with an increased risk for military personnel.^{2,3} Although there has been progress in the identification of potential targets for the disease, and many new therapeutics have been tested in animals and in clinical trials over the last two decades,⁴ no effective treatment is currently available; the only FDA-approved drug, riluzole, a presumptive ant glutamatergic drug, extends survival by only 2–3 months.⁵

Although ALS is principally a sporadic disease, approximately 10% of all cases are familial (FALS), and over 100 genes are potentially responsible for FALS.⁶ Mutations in Cu/Zn superoxide dismutase (SOD1) are the most common cause of FALS.⁷ Although mutations in SOD1 account for only 2% of ALS patients, it has recently been shown that astrocytes from both FALS and sporadic ALS (SALS) patients are similarly toxic to motor neurons and that knockdown of SOD1 significantly attenuates astrocyte-mediated toxicity of motor

neurons, indicating that SOD1 is a viable target for SALS.⁸ Also, because mutant SOD1 leads to oxidative stress, protein misfolding, and aggregation, all of which are associated with ALS pathogenesis,⁹ it is reasonable to include inhibitors of mutant SOD1-induced protein aggregation as a viable strategy to identify novel ALS therapeutics.


Three different scaffolds, arylsulfanylpyrazolones (ASP), pyrimidine-2,4,6-triones (PYT), and cyclohexane-1,3-diones (CHD), were identified by a high-throughput cell-based screen¹⁰ based on cell lines developed by Morimoto and co-workers.¹¹ Extensive modification of the ASP^{12,13} and PYT¹⁴ leads afforded excellent therapeutic candidates, with favorable potency, pharmacokinetics, toxicity, and life extension in the ALS mouse model. However, the most potent of the CHD derivatives did not show any significant extension of life in the ALS mouse model, despite having comparable potency in the PC-12 cell assay and favorable pharmacokinetic properties.¹⁵ Aggregation of mutant G93A SOD1 is induced in the PC-12

Received: April 19, 2012

Accepted: May 22, 2012


Published: May 22, 2012

assay, which produces a concomitant loss in cell viability. Cell viability is restored through treatment with compounds that reduce protein aggregation. The proposed explanation was the lack of *in vitro* activity in cortical neurons. Two racemic analogues (**1** and **2**) were identified with enhanced activity in cortical neurons that retained their activity in the PC-12 assay. Here we have synthesized the enantiomers of the active compounds and show that both enantiomers of each scaffold penetrate cortical neurons, that the pharmacokinetics of the eutomers are favorable, and that one of the isomers produces a slightly greater extension of life in the ALS mouse model than riluzole, the only FDA-approved drug for ALS.



As shown in Scheme 1, starting from commercially available ethyl lactate (**3**) and 3,5-difluoromethyl phenol (**4**), the

Scheme 1. Synthesis of **1**^a




^aReagents and conditions: (a) PPh₃, DEAD, THF, room temp, overnight, 98%; (b) DIBAL, DCM, -78 °C, 1 h, 96%; (c) 1-(triphenylphosphoranylidene)-2-propanone, THF, room temp, overnight, 82%; (d) diethyl malonate, EtONa, EtOH, room temp, overnight; (e) 2 N NaOH, room temp, 4 h; (f) 1 N HCl, 90 °C, 1 h, 53% for the three steps.

condensed ether (**5**) was formed using a Mitsunobu reaction. Treatment with DIBAL at -78 °C provided aldehyde **6** in a high yield, which was used directly in a Wittig reaction to afford enone **7** in a 5:1 *trans* to *cis* ratio. A one-pot procedure, which includes a Michael addition, cyclization, hydrolysis, and decarboxylation, was carried out to give **1** in high yield; starting from chiral ethyl lactates, the two enantiomers (**1a** and **1b**) were readily obtained.

The route shown in Scheme 2 was used to synthesize **2**. 3,5-Difluoromethyl benzaldehyde (**8**) was treated with triethyl phosphonoacetate and then reduced to obtain mostly *trans*-allyl alcohol **9** in 67% yield. An enantioselective Simmons–Smith cyclopropanation was performed with bifunctional boron ester **10**¹⁶ in a high yield and excellent enantioselectivity. The alcohol intermediate (**11**) was converted to an enone (**12**) by PCC oxidation and a Wittig reaction. A one-pot procedure of a Michael addition, cyclization, hydrolysis, and decarboxylation was carried out to give *trans*-**2**. This method was used to

Scheme 2. Synthesis of **2**^a



^aReagents and conditions: (a) Triethyl phosphonoacetate, NaH, THF, 0 °C → room temp, overnight; (b) DIBAL, DCM, 0 °C, 2 h, 67% for the two steps; (c) CH₂I₂, ZnEt₂, DCM, 0 °C → room temp, overnight, 88%; (d) PCC, silica gel, DCM, room temp, 3 h; (e) 1-(triphenylphosphoranylidene)-2-propanone, THF, room temperature, overnight, 58% for the two steps; (f) diethyl malonate, EtONa, EtOH, room temp, overnight; (g) 2 N NaOH, room temp, 4 h; (h) 1 N HCl, 90 °C, 1 h, 47% for the three steps.

synthesize the enantiomers of **2**, starting from the enantiomers of **11**.

Compound activity was assessed using a previously described cytotoxicity protection assay.¹⁰ The EC₅₀ values of these analogues are summarized in Figure 1. The potencies of the




Figure 1. Cytotoxicity protection assay for the CHD analogues.

ether linker CHD (**1**) were superior to those of the cyclopropyl linker compounds (**2**). The enantiomers of the ether linker analogues (**1a** and **1b**) showed a greater potency difference than their cyclopropyl counterparts (**2a** and **2b**); *S*-enantiomer **1b** was 4–5-fold more potent than *R*-enantiomer **1a**, but **2b** was only 1.5–2-fold more potent than **2a**. Ether **1b** was the most potent among all of the CHD analogues tested.¹⁵

It was previously found that **13** had little or no effect on life extension in the ALS mouse model and was not active with cortical neurons. As shown in Figure 2, all of the compounds in Figure 1 had cortical neuron activity except **13**. Furthermore, compound **1b** exhibited more than 90% neuronal activity at 3 μM, while, as a control, the best ASP compound (see Figure 2) required a concentration of 10 μM to reach maximum recovery. The aqueous solubilities of **1b** and **2b** were evaluated by dilution from a stock solution in DMSO to a final




Figure 2. Qualitative primary cortical neurons protection assay. Reference: compound 13 in ref 13.

concentration of 1% DMSO in PBS. The solubility limit was the highest concentration with no precipitation. Both compounds were found to have high aqueous solubility¹⁷ ($\geq 100 \mu\text{M}$).

The in vitro plasma stability half-life for **1b** was >60 min, and that for **2b** was 71 min. The human and mouse microsomal stabilities of these compounds were tested at $1 \mu\text{M}$ at 37°C for 1 h in the presence and absence of NADPH (Table 1). Both of

Table 1. In Vitro Microsomal Stability of **1b** and **2b**^a

compd	NADPH-dependent		NADPH-absent		
	CL_{int}^b (mL min ⁻¹ kg ⁻¹)	$T_{1/2}^c$ (min)	CL_{int}^b (mL min ⁻¹ kg ⁻¹)	$T_{1/2}^c$ (min)	
human	1b	31	74	10	>180
	2b	36	64	12	>180
mouse	1b	45	52	45	52
	2b	82	28	63	37

^aData were obtained from Aprelica. ^bMicrosomal intrinsic clearance. ^cHalf-life.

the compounds showed moderate clearance with human liver microsomes (31–36 mL/(min kg)) and moderate to near high clearance with mouse liver microsomes (45–82 mL/(min kg));¹⁸ both had half-lives in human microsomes greater than 1 h. Metabolite identification studies indicated the only metabolic product was insertion of an oxygen atom somewhere other than on the bis(trifluoromethyl)phenyl ring (see Supporting Information).

Compounds **1b** and **2b** were further evaluated for their ability to penetrate Caco-2 cell monolayers, which is correlated with intestinal permeability in vivo. As shown in Table 2, both

Table 2. In Vitro Caco-2 Permeability of **1b** and **2b**^a

compd	P_{app} (A→B) ^b (10^{-6} cm/S)	P_{app} (B→A) ^b (10^{-6} cm/S)	efflux ratio (B→A)/(A→B)
1b	24.1	1.5	0.1
2b	21.7	1.1	0.1

^aData were obtained from Aprelica. ^bApparent permeability.

had high permeability from the A side to the B side. Moreover, the low efflux ratio ($P_{app}(B\rightarrow A)/P_{app}(A\rightarrow B)$) indicates these compounds are unlikely to be substrates of efflux transport proteins, which is especially important for CNS drugs. Compound **1b** was selected for in vivo testing on the basis of its potency and in vitro predicted pharmacology profile.

Maximum blood levels ($245 \mu\text{M}$) of **1b** by ip administration (500 mg/kg) occurred at 12 h, the blood half-life; brain penetration was $8.3 \mu\text{M}$ with a T_{max} of 12 h. As the commonly used ALS animal model, transgenic mice expressing human G93A mutant SOD1 develop a series of similar symptoms to those observed in both familial and sporadic ALS patients.¹⁹ Control and transgenic mice of the same age (± 3 days) and from the same “F” generation were selected from multiple litters to form experimental cohorts. The tolerable dose range for **1b** was determined in wild-type mice by increasing the dose b.i.d., and the maximum tolerated dose was 1280 mg/kg. On the basis of the ADME and MTD studies, the dose levels of 10, 20, and 30 mg/kg were administered daily, starting from 6 weeks of age to the end of life of the G93A mice. Administration of **1b** resulted in a 13% extension in survival at 20 mg/kg compared to the case of untreated G93A mice (Figure 3). This result is slightly better than that observed for the only FDA approved drug riluzole, which showed a lifespan extension of 10–11% at 22 mg/kg in the same animal model.²⁰




Figure 3. Kaplan–Meier plot of **1b**-treated SOD1 G93A ALS mice: untreated group, 125.7 ± 4.3 days; group 1 (10 mg/kg), 139.2 ± 8.3 days; group 2 (20 mg/kg), 142.0 ± 9.1 days ($p < 0.03$); group 3 (30 mg/kg), 127.9 ± 4.7 days ($p < 0.63$).

Previously, we had prepared a compound (**13**) that was a potent inhibitor of protein aggregation in PC-12 cells expressing mutant G93A SOD1 with very good pharmacokinetic properties but which was inactive in vivo in the ALS mouse model. It was found to be inactive in cortical neurons, which led to the design of two racemic compounds (**1** and **2**) that were active in cortical neurons. Chiral syntheses of the enantiomers of **1** and **2** were carried out, and both enantiomers of each compound were found to be active in both the PC-12 and cortical neuron assays. The eutomers of each racemic compound (**1b** and **2b**) had good pharmacokinetic properties, and the more potent of these (**1b**) was shown to extend the life of the ALS mouse by 13%, which is slightly better than that previously reported for riluzole, the only FDA-approved drug for ALS, in the same mouse model. These studies demonstrate the importance of investigating the cortical neuron activity of compounds prior to the expensive and time-consuming task of an ALS mouse trial. They also validate the cyclohexane 1,3-dione class of compounds as a potential therapeutic scaffold for the treatment of ALS.

■ ASSOCIATED CONTENT

■ Supporting Information

Detailed description of experimental procedures, biological evaluations, and characterization of **1** and **2**. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

*Tel: 847-491-5663. Fax: 847-491-7713. E-mail: Agman@chem.northwestern.edu.

Funding

We thank the National Institutes of Health (Grant 1R43NS057849), the ALS Association (TREAT program), and the Department of Defense (AL093052), for their generous support of this research.

Notes

The authors declare no competing financial interest.

■ ABBREVIATIONS

ADME, absorption, distribution, metabolism, excretion; ALS, amyotrophic lateral sclerosis; CHD, cyclohexane 1,3-dione; CNS, central nervous system; FALS, familial ALS; PBS, phosphate buffered saline; PK, pharmacokinetics; SALS, sporadic ALS; SOD1, Cu/Zn superoxide dismutase

■ REFERENCES

- (1) Rowland, L. P.; Shneider, N. A. Amyotrophic lateral sclerosis. *N. Engl. J. Med.* **2001**, *344*, 1688–1700.
- (2) Cronin, S.; Hardiman, O.; Traynor, B. J. Ethnic variation in the incidence of ALS. *Neurology* **2007**, *68*, 1002–1007.
- (3) Weisskopf, M. G.; O'Reilly, E. J.; McCullough, M. L.; Calle, E. E.; Thun, M. J.; Cudkovic, M.; Ascherio, A. Prospective study of military service and mortality from ALS. *Neurology* **2005**, *64*, 32–37.
- (4) Zinman, L.; Cudkovic, M. Emerging targets and treatments in amyotrophic lateral sclerosis. *Lancet Neuro.* **2011**, *10*, 481–490.
- (5) Bensimon, G.; Lacomblez, L.; Meininger, V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. *N. Engl. J. Med.* **1994**, *330*, 585–591.
- (6) See <http://alsod.iop.kcl.ac.uk/>, the ALS online genetics database.
- (7) Brown, R. H., Jr.; Robberecht, W. Amyotrophic lateral sclerosis: pathogenesis. *Semin. Neurol.* **2001**, *21*, 131–139.
- (8) Haidet-Phillips, A. M.; Hester, M. E.; Miranda, C. J.; Meyer, K.; Braun, A.; Frakes, L.; Song, S. W.; Likhite, S.; Murtha, M. J.; Foust, K. D.; Rao, M.; Eagle, A.; Kammesheidt, A.; Christensen, A.; Mendell, J. R.; Burghes, A. H. M.; Kaspar, B. K. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. *Nat. Biotechnol.* **2012**, *29*, 824–830.
- (9) Bosco, D. A.; Morfini, G.; Karabacak, N. M.; Song, Y.; Gros-Louis, F.; Pasinelli, P.; Goolsby, H.; Fontaine, B. A.; Lemay, N.; McKenna-Yasek, D.; Frosch, M. P.; Agar, J. N.; Julien, J. -P.; Brady, S. T.; Brown, R. H., Jr. Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. *Nat. Neurosci.* **2010**, *13*, 1396–1403.
- (10) Benmohamed, R.; Arvanites, A. C.; Silverman, R. B.; Morimoto, R. I.; Ferrante, R. J.; Kirsch, D. R. Identification of compounds protective against G93A SOD1 toxicity for the treatment of amyotrophic lateral sclerosis. *Amyotrophic Lateral Scler.* **2011**, *12*, 87–96.
- (11) Matsumoto, G.; Stojanovic, A.; Holmber, C. I.; Kim, S.; Morimoto, R. I. Structure properties and neuronal toxicity of amyotrophic lateral sclerosis-associated Cu/Zn superoxide dismutase 1 aggregates. *J. Cell Biol.* **2005**, *171*, 75–85.
- (12) Chen, T.; Benmohamed, R.; Arvanites, A. C.; Ranaivo, H. R.; Morimoto, R. I.; Ferrante, R. J.; Watterson, D. M.; Kirsch, D. R.; Silverman, R. B. Arylsulfanyl pyrazolones block mutant SOD1-G93A

aggregation. Potential application for the treatment of amyotrophic lateral sclerosis. *Bioorg. Med. Chem.* **2011**, *19*, 613–622.

(13) Chen, T.; Benmohamed, R.; Kim, J.; Smith, K.; Amante, D.; Morimoto, R. I.; Ferrante, R. J.; Kirsch, D.; Silverman, R. B. ADME-guided design and synthesis of aryloxanylpyrazolonone derivatives to block mutant superoxide dismutase 1 (SOD1) cytotoxicity and protective aggregation: Potential application for the treatment of amyotrophic lateral sclerosis. *J. Med. Chem.* **2012**, *55*, 515–527.

(14) Xia, G.; Benmohamed, R.; Kim, J.; Arvanites, A. C.; Morimoto, R. I.; Ferrante, R. J.; Kirsch, D.; Silverman, R. B. Pyrimidine-2,4,6-trione derivatives and their inhibition of mutant SOD1-dependent protein aggregation. Toward a treatment for amyotrophic lateral sclerosis. *J. Med. Chem.* **2011**, *54*, 2409–2421.

(15) Zhang, W.; Benmohamed, R.; Arvanites, A. C.; Morimoto, R. I.; Ferrante, R. J.; Kirsch, D. R.; Silverman, R. B. Cyclohexane 1,3-diones and their inhibition of mutant SOD1-dependent protein aggregation and toxicity in PC12 cells. *Bioorg. Med. Chem.* **2012**, *20*, 1029–1045.

(16) Charette, A. B.; Juteau, H. Design of amphoteric bifunctional ligands: Application to the enantioselective Simmons-Smith cyclopropanation of allylic alcohols. *J. Am. Chem. Soc.* **1994**, *116*, 2651–2652.

(17) Kerns, E. H.; Di, L. *Drug-like Properties: Concepts, Structure, Design, and Methods*; Academic Press: 2008; p 65.

(18) Nassar, A. F. *Drug metabolism Handbook: Concepts and applications*; Wiley: 2009; p 150.

(19) Gurney, M. E.; Pu, H.; Chiu, A. Y.; Dal Canto, M. C.; Polchow, C. Y.; Alexander, D. D.; Caliendo, J.; Hentati, A.; Kown, Y. W.; Deng, H. X.; Chen, W.; Zhai, P.; Sufit, R. L.; Siddique, T. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. *Science* **1994**, *264*, 1772–1775.

(20) Gurney, M. E.; Cutting, F. B.; Zhai, P.; Doble, A.; Taylor, C. P.; Andrus, P. K.; Hall, E. D. Benefit of vitamin E, riluzole, and gabapentin in transgenic model of familial amyotrophic lateral sclerosis. *Ann. Neurol.* **1996**, *39*, 147–157.